About

About Illumind Therapeutics Illumind Therapeutics is a clinical-stage neuropsychiatry company focused on developing novel treatments for post-traumatic stress disorder (PTSD) and related anxiety disorders. The company leverages a mechanism-driven approach targeting dysfunctional neural plasticity and circuit dysregulation. Illumind’s strategy centers on the rational combination of pharmacologic agents with complementary mechanisms of action to restore functional balance within key neurobiological pathways. By integrating existing compounds with established safety profiles into innovative therapeutic paradigms, the company aims to accelerate clinical development while reducing risk. The lead program is advancing toward mid-stage clinical evaluation (Phase 2b) in PTSD, with a focus on achieving rapid, sustained symptom improvement through modulation of glutamatergic signaling and downstream network effects. Illumind operates at the intersection of translational neuroscience and clinical execution, with a model designed to efficiently move from mechanistic insight to patient impact. The company is actively seeking strategic partnerships to support clinical development, regulatory advancement, and global commercialization.